Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC introduces new treatment for canine heart condition
The surgery is minimally invasive, with quick recovery times.
The new procedure helps treat degenerative mitral valve disease (DMVD).

The Royal Veterinary College (RVC) has become the first centre in the world to offer a new treatment for dogs with degenerative mitral valve disease (DMVD) alongside open-heart surgery and medical treatment.

The new treatment option, trans-catheter edge-to-edge repair (TEER), is minimally-invasive and is now available at the RVC’s Queen Mother Hospital for Animals (QMHA).

DMVD causes the mitral valve to thicken and become leaky, and so blood will flow backwards into the heart’s left atrium. This means the heart chambers will enlarge, often resulting in heart failure.

The condition is most frequent in smaller, older dogs. Although it is incurable, it is managed with medication and treatment to extend life.

The introduction of TEER, which is a relatively new procedure, is the result of collaboration between QMHA’s Cardiology Service and Bristol Veterinary Specialists. The procedure is undertaken using specialist equipment, including the hospital’s echo machines.

The surgery is minimally invasive, which allows surgeons to repair the mitral valve on a beating heart. Dogs are mobile the following day and are usually discharged within two days.

TEER is offered alongside open-heart surgery under cardiopulmonary bypass, which is still considered the most effective therapy for advanced cases of DMVD.

However, researchers suggest that TEER may be recommended to patients unsuitable for open-heart surgery, those requiring a less invasive approach, and those with financial limitations. It is also recommended to dogs with severe mitral regurgitation caused by DMVD, heart enlargement or a history of congestive heart failure.

Joshua Hannabuss, lecturer in veterinary cardiology and co-head of cardiology at RVC’s QMHA, said: "It's truly exciting to offer an additional treatment option for dogs with degenerative mitral valve disease. I believe we’re entering a new era where minimally invasive therapies will become more accessible for managing this condition.

“With a clearer understanding of the safety, benefits and potential risks of TEER, we feel that now is the right time to introduce this therapy to the UK, and we remain committed to improving the quality and longevity of life for dogs affected by this disease."

Image © Tymoshenko Olga/Shutterstock.com

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.